leadf
logo-loader
viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies adds biotechnology executive Dr Stefan Lang as chief business officer

The new executive will be responsible for corporate and business development activities as well as corporate and product strategic planning

boardroom table
Lang has over 20 years of executive experience in the biotechnology industry

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) is bolstering its executive team with the appointment of Dr Stefan Lang to the newly-created role of chief business officer.

Lang has over 20 years of executive experience in the biotechnology industry and most recently served as the vice president of business development at Aldevron LLC, a custom producer of nucleic acids, proteins, and antibodies.

The new executive will be responsible for ImmunoPrecise Antibodies' corporate and business development activities as well as corporate and product strategic planning.

READ: ImmunoPrecise Antibodies aiming to enhance value of its IP; reports debenture extension

“(Dr Lang) brings an impressive breadth of leadership expertise in the biotech industry, including experience working at the organizational level and as a globally-recognized and respected leader in antibody business development," said Dr Jennifer Bath, CEO of ImmunoPrecise in a statement.

"We look forward to Dr. Lang's insightful contributions as we pursue our mission of transforming next generation antibody therapeutics and diagnostics."

Lang said he was “thrilled” to join the Victoria-based company. "In only a few years, ImmunoPrecise has established itself as a leader in the antibody discovery space, with a clear vision and the technical capabilities to become the preferred partner of choice for this industry."

“I see tremendous opportunity to build on this progress and I am eager to lend my expertise to ImmunoPrecise as the partner-of-choice for biopharmaceutical companies pursuing antibody discovery in immunotherapies and diagnostics,” he added.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twiiter @AHarmantas

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 2.02 CAD

TSX-V:IPA
Market: TSX-V
Market Cap: $161.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

ImmunoPrecise Antibodies reveals 39% growth in 1Q revenue, initiates...

ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new...

4 weeks ago

2 min read